PemOla

Protocol Title

A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden ≥ 4 mutations/Mb.

Purpose of the Study

Pancreatic adenocarcinoma (PDAC) is one of the 10 most common cancer types. Despite modern interventions, outcomes have changed little in the last 50 years and PDAC is projected to be the second most common cause of cancer death by 2030. Up to 80% of patients are diagnosed with the disease too late for surgery and median survival with metastatic pancreatic adenocarcinoma (mPDAC) is under 1 year even with optimal chemotherapy. Developing more effective treatments for mPDAC is a global unmet need. Precision medicine approaches to PDAC are attractive given the heterogeneity of this disease and the poor outcomes with conventional chemotherapy.

Currently, immunotherapy is not routinely established as an effective treatment for patients with metastatic pancreatic cancer. The study aims to understand whether patients with metastatic pancreatic cancer will respond well to immunotherapy comprising of the two drugs, pembrolizumab and olaparib.

Contact Email

GCT_PemOla_Mailbox@gicancer.org.au

DETAILED INFORMATION AVAILABLE

More detailed information available online at ClinicalTrials.gov, and ANZCTR.

STUDY CHAIRS

A/Prof Dan Croagh
A/Prof Sumitra Ananda

FUNDING

GI Cancer Trials (formerly AGITG) Philanthropic funding
2023 Tour De Cure Grant
2023 PanKind Australian Pancreatic Cancer Foundation Limited Research Grant
2023 Epworth Medical Foundation Grant